Related Experiment Video
Updated: Nov 2, 2025
A Mouse Model for Vascular Cognitive Impairment and Dementia Based on Needle-guided Asymmetric Bilateral Common Carotid Artery Stenosis
Published on: November 22, 2024
ACTION OF SIMVASTATIN IN IMPROVING COGNITIVE FUNCTIONS IN VASCULAR DEMENTIA
T Lazashvili1, T Silagadze1, V Kapetivadze1
1Tbilisi State Medical University, Department of Internal Disease of Propedeutics, Georgia.
Insights
This study found that statins did not improve cognitive function in vascular dementia patients, despite lowering cholesterol. Lipid metabolism correction with statins showed no clinical benefit for cognitive impairment in this patient group.
Area of Science:
- Neurology
- Cardiology
- Pharmacology
Background:
- Vascular dementia is often caused by atherosclerotic vascular lesions.
- Lipid metabolism disorders and dyslipidemia are key factors in vascular dementia.
- Statins are commonly used to manage dyslipidemia.
Purpose of the Study:
- To evaluate the efficacy and safety of statins in enhancing cognitive function in vascular dementia patients.
- To assess the impact of lipid-lowering therapy on cognitive decline in this population.
Main Methods:
- A 12-week randomized controlled trial involving 31 patients (20 in the study group, 11 in the control group).
- The study group received Simvastatin (80 mg daily), while the control group received a placebo.
- Cognitive function was assessed using mini-mental state examination, and lipid profiles (LDL, cholesterol) were measured pre- and post-treatment.
Main Results:
- Simvastatin treatment significantly reduced low-density lipoprotein (LDL) by 54% and cholesterol by 48%.
- Despite lipid level improvements, no significant difference in cognitive function was observed between the statin and placebo groups.
- Neuropsychological testing indicated a deterioration of cognitive functions in both groups over the study period.
Conclusions:
- Lipid metabolism correction using statins did not improve cognitive impairment in patients with vascular dementia.
- Current statin therapy does not appear to offer clinical benefits for cognitive function in vascular dementia.
- Further research is needed to explore alternative therapeutic strategies for cognitive enhancement in vascular dementia.
Abstract:
The purpose of this study was to determine the efficacy and safety of statins in improving cognitive function in patients with vascular dementia. As the most important etiological factors of the disease are atherosclerotic vascular lesions, one of the important areas of treatment is lipid metabolism analysis and drug treatment for dyslipidemia. 31 patients were selected for the study, ages 65-65 years, 18 males, 13 females. Twenty patients were included in the study group, treated with Simvastatin (80 mg daily dose). 11 patients were included in the control group. They received placebo therapy. Patients were examined every 4 weeks for 12 weeks using a neuropsychological test with mini-mental scaling, and both groups had low-density lipoprotein and cholesterol levels before and after treatment. In the 12-week post-treatment group, low-density lipoprotein levels were reduced by 54% and cholesterol by 48%. Neuropsychological status examination revealed deterioration of cognitive functions and no difference was observed between study and control group data. Based on the data obtained from our study, it should be noted that correction of lipid metabolism by statins in patients with vascular dementia did not lead to a reduction in cognitive impairment and clinical improvement in patients with vascular dementia.
Related Concept Videos
01:30Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
01:22Alzheimer's Disease: Treatment
01:26Atherosclerosis III: Management
01:20Lipid-Lowering Drugs: Statins and Miscellaneous Agents
01:26Alzheimer's Disease: Overview
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
01:23Atherosclerosis IV: Nursing Management